Articles related to GLP-1s

“We are recommending that if patients are starting these drugs or increasing the dose of these drugs, they should do so slowly to reduce the risk of dropping their blood sugar and causing an osmotic shift.”

The study demonstrated a reduced risk of suicidal thoughts and self-harm among people using GLP-1 drugs.

In a systematic review of 26 randomized controlled trials involving over 15,000 participants, tirzepatide demonstrated weight reduction of 17.8% at 72 weeks, while newer agents like retatrutide achieved up to 22.1% reduction at 48 weeks, providing clinicians with expanded options for pharmacological weight management.

The preservation of Medicare drug price negotiations alongside the removal of other cost-reduction measures creates a complex landscape for healthcare delivery and patient access.

Adverse events from compounded semaglutide have led to hundreds of hospitalizations, highlighting critical safety concerns for healthcare providers managing patients seeking weight loss solutions.

The combination of structured lifestyle interventions with targeted pharmacotherapy demonstrates significant potential for achieving substantial weight loss in patients with type 2 diabetes.